A new single-tablet HIV regimen containing tenofovir alafenamide (TAF) offered better bone and kidney safety, according to a study presented at ICAAC/ICC 2015.
Douglas Dieterich, M.D., who specializes in liver disease at Mount Sinai Hospital, discusses the new generation of medications against hepatitis C (HCV).
This year at CROI, there were over 30 abstracts on cardiovascular disease and HIV, which is a noticeable increase from prior years. Here's a recap of some of those studies.
Handling metabolic issues in HIV-positive patients requires a "multifactorial solution particularly emphasizing lifestyle modification."
With the deaths of 500 health care workers in West Africa due to Ebola, the epidemic has brought on a public health emergency in a region that already has a shortage of care providers and resources.
The use of varenicline (Chantix) appears to be relatively safe in people living with HIV, and when combined with counseling, could significantly increase the number who are able to quit smoking, according to a CROI 2015 study.
The new formulation of tenofovir, tenofovir alafenamide (TAF), was associated with less harm to bones and kidneys than the older formulation, tenofovir disoproxil fumarate (TDF, Viread).
"Mission Accomplished," the title given by CROI 2015 organizers for the session on hepatitis C (HCV) treatment, was premonitional. Two big phase-3 studies in HIV/HCV coinfected individuals were presented.
In the ION-4 study, 335 patients received tw...
Having a high viral load when starting treatment was most consistently associated with body composition changes after starting antiretroviral therapy.
Results from a study of 335 HCV/HIV coinfected patients showed a cure rate of 96%, offering compelling evidence that coinfected persons can be treated for hepatitis C with a once-daily regimen.